Command Palette

Search for a command to run...

JBCHEPHARM

1668.1-0.31%
Market Cap
₹26,222.04 Cr
Stock P/E
38.27
ROCE
26.73%
ROE
21.81%
Book Value
₹221.45

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

J.B. Chemicals & Pharmaceuticals Open Offer: Corrigendum Issued

Other Updates
9/100
1 month ago

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

POSITIVES
  • Q1 top-line growth and net profit uplift.
  • Margin expansion supports profitability (gross 68.3%, EBITDA 30.2%).
NEGATIVES
  • M&A regulatory risk due to pending approvals from CCI and others.
  • International export markets showed weakness (2% YoY decline in International Formulations).

Peers Summary

Sector Leader

JB Chemicals & Pharmaceuticals Ltd. showcases strong growth and profitability metrics relative to its peers. While it exhibits a competitive ROE and revenue growth, it is also well-positioned in terms of valuation, making it a compelling choice in the pharmaceuticals sector. Companies like Cipla and Dr. Reddy's also stand out for their strong profitability, while others like Divi's Laboratories face challenges despite high valuations.

Key Points
  • JB Chemicals has robust revenue growth of 10.63% YoY and a healthy ROE of 21.49%.
  • Cipla and Dr. Reddy's are notable for their strong profitability metrics with attractive PE ratios.
  • Divi's Laboratories is facing significant declines in revenue growth despite high valuations.
Top Performers
Cipla Ltd.

High profitability metrics with a PE of 23.73 and solid revenue growth of 13.28% YoY.

Dr. Reddy's Laboratories Ltd.

Strong profitability with a low PE of 15.50 and substantial revenue growth of 16.54% YoY.

JB Chemicals & Pharmaceuticals Ltd.

Competitive growth and profitability metrics with a PE of 41.33 and revenue growth of 10.63% YoY.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.